List of Oforta drug patents
Oforta is owned by Sanofi Aventis Us.
Oforta contains Fludarabine Phosphate.
Oforta has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Oforta are:
- US7148207
Oforta was authorised for market use on 18 December, 2008.
Oforta is available in tablet;oral dosage forms.
Oforta can be used as treatment of patients with b-cell chronic lymphocytic leukemia (cll).
The generics of Oforta are possible to be released after 20 December, 2022.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7148207 | SANOFI AVENTIS US | Oral fludara of high-purity formulation with quick release of active ingredient |
Dec, 2022
(3 months ago) | |
Drugs and Companies using FLUDARABINE PHOSPHATE ingredient
Market Authorisation Date: 18 December, 2008
Treatment: Treatment of patients with b-cell chronic lymphocytic leukemia (cll)
Dosage: TABLET;ORAL
OFORTA family patents
2
Germany
2
United States
2
Japan
2
European Union
1
Israel
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Australia
1
Saudi Arabia
1
Hong Kong
1
Russia
1
Jordan
1
Uruguay
1
Norway
1
Argentina
1
Brazil
1
Croatia
1
Yugoslavia
1
Spain
1
Korea, Republic of
1
Peru
1
Poland
1
Taiwan, Province of China
1
China
1
Ecuador
1
Ukraine
1
Canada
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic